Skip to content

Differences in Clinical Characteristics of Attention-Deficit/Hyperactivity Disorder Subtypes Based on Urinary Biomarker Detection and Their Relationship with Executive Function

Differences in Clinical Characteristics of Attention-Deficit/Hyperactivity Disorder Subtypes Based on Urinary Biomarker Detection and Their Relationship with Executive Function

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113413
Enrollment
Unknown
Registered
2025-11-27
Start date
2025-11-30
Completion date
Unknown
Last updated
2025-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-Deficit/Hyperactivity Disorder (ADHD)

Interventions

ADHD group:N/A
Healthy control group:N/A

Sponsors

Weifang Maternal and Child Health Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
5 Years to 12 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for the ADHD group: 1. Meet the diagnostic criteria for ADHD as outlined in the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) of the American Psychiatric Association (all subjects required to undergo the Mini-kid interview); 2. Aged 5 to 12 years; 3. Intelligence within the normal range, with a Full Scale Intelligence Quotient (FSIQ) of =80 as assessed by the Wechsler Intelligence Scale; 4. The parents or guardians of the child participants have been informed about the study protocol and have voluntarily provided written informed consent. Healthy control group: 1. Age 5-12 years; 2. IQ score = 80.

Exclusion criteria

Exclusion criteria: ADHD group: 1. Individuals with hyperactivity symptoms secondary to conditions such as epilepsy, Tourette's syndrome, intellectual developmental delay/disorder, or other neuropsychiatric disorders; 2. Those with hearing or visual abnormalities; 3. Individuals with a past or current comorbid diagnosis of other psychiatric disorders, such as childhood schizophrenia, mood disorders, or autism spectrum disorder; 4. Individuals with conditions such as brain injury, severe physical illnesses, neurological abnormalities, or impaired consciousness; 5. Those with a history of using psychotropic medications. Healthy control group: 1. More than 4 items scored on attention deficit or hyperactivity-impulsivity on the ADHD symptom rating scale; 2. Hearing or vision abnormalities; 3. Past or current psychiatric disorders; 4. Serious physical illnesses, neurological abnormalities, or consciousness disorders; 5. History of psychiatric medication use.

Design outcomes

Primary

MeasureTime frame
MINI International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)t;Swanson, Nolan, and Pelham Rating, Version IV (SNAP-IV);Executive Function in Children;Comprehensive Biochemical ; Ferritin;Vitamin D;Zinc;Copper;Thyroid Function;High-sensitivity C-reactive protein (hs-CRP);Urine Biomarker;

Secondary

MeasureTime frame
Wechsler Intelligence for Children;Conners' Rating ;Child Behavior Checklist (CBCL);Child Emotional, Social, and Temperamental;

Countries

China

Contacts

Public ContactLi Yin

Weifang Maternal and Child Health Hospital

yinli20152015@126.com+86 156 5361 0369

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026